Alberto Moriggia
Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort
Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer M, Vernazza P, Scheidegger C. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. Swiss Med Wkly 2021; 151:w20460.
Mar 4, 2021Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort
Mar 4, 2021Swiss Med Wkly 2021; 151:w20460
Bregenzer Andrea, Bruggmann Philip, Castro Erika, Moriggia Alberto, Rothen Madeleine, Thurnheer Maria Christine, Vernazza Pietro, Scheidegger Claude
Nonalcoholic fatty liver disease burden - Switzerland 2018-2030
Goossens N, Semela D, Razavi H, Negro F, Muellhaupt B, Moriggia A, Mertens J, Jornayvaz F, Dufour J, Cerny A, Bellentani S, Estes C. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. Swiss Med Wkly 2019; 149:w20152.
Dec 17, 2019Nonalcoholic fatty liver disease burden - Switzerland 2018-2030
Dec 17, 2019Swiss Med Wkly 2019; 149:w20152
Goossens Nicolas, Semela David, Razavi Homie, Negro Francesco, Muellhaupt Beat, Moriggia Alberto, Mertens Joachim, Jornayvaz François R, Dufour Jean-François, Cerny Andreas, Bellentani Stefano, Estes Chris
Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?
Bertisch B, Keiser O, Moradpour D, Zehnder C, Marinucci F, Roelens M, Moriggia A, Clerc O, Giudici F, Schmid P, Künzler-Heule P, Ottiger C, Mullhaupt B, Negro F, Brezzi M, Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?. Clin Infect Dis 2019
Apr 3, 2019Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?
Apr 3, 2019Clin Infect Dis 2019
Bertisch Barbara, Keiser Olivia, Moradpour Darius, Zehnder Cinzia, Marinucci Francesco, Roelens Maroussia, Moriggia Alberto, Clerc Olivier, Giudici Fabio, Schmid Patrick, Künzler-Heule Patrizia, Ottiger Cornelia, Mullhaupt Beat, Negro Francesco, Brezzi Matteo, Swiss Hepatitis C Cohort Study
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy 2018; 62:94-103.
Oct 29, 2018Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Oct 29, 2018Int J Drug Policy 2018; 62:94-103
Grebely Jason, Feld Jordan J, Bruneau Julie, Daulouede Jean-Pierre, Powis Jeff, Bruggmann Philip, Matthews Gail V, Kronborg Ian, Shaw David, Dunlop Adrian, Hellard Margaret, Applegate Tanya L, Crawford Sione, Dore Gregory J, Lacombe Karine, Dalgard Olav, Conway Brian, Cunningham Evan B, Fraser Chris, Moriggia Alberto, Gane Ed, Stedman Catherine, Cooper Curtis, Castro Erika, Schmid Patrick, Petoumenos Kathy, Hajarizadeh Behzad, Marks Phillipa, Erratt Amanda, D3FEAT Study Group